treatment of HIV

The Expert Committee on the Office of the U.S. Food and Drug Administration USA (Food and Drug Administration - FDA) called for a vote of 16:0 approval of the drug tezamorelin Canadian company «Theratechnologies Inc.», For the treatment of abdominal obesity in patients with HIV suffering from lipodystrophy. The recommendation is based on the Vardenafil 20mg results of the study, which showed a favorable benefit / risk in the treatment of HIV? Infected patients with lipodystrophy. FDA will make the final decision regarding the approval of the product until 27 July this year.



Roscon Yves (Yves Rosconi), CEO «Theratechnologies», noted that the recommendation of experts is particularly significant for patients with this serious metabolic disorder, for which exists at this time of any treatment. "This is also a significant step forward for the company ... which to achieve this result, it took 15 years", - said the head of «Theratechnologies».



If final approval tezamorelina in the U.S. «Theratechnologies» will marketirovat in conjunction with the company «EMD Serono Inc.», American and Canadian division of the German «Merck KGaA».